Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing...

